Sudeep pharma limited IPO Overview
Sudeep pharma limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹895.00 Cr. The IPO price band is set at ₹563 to ₹593 per share, and retail investors can apply with a minimum investment of ₹14,825 as per IPO guidelines.
The Sudeep pharma limited IPO opens on 21 Nov 2025 and closes on 25 Nov 2025. The IPO allotment is expected to be finalized on 26 Nov 2025, and the equity shares are proposed to be listed on BSE,NSE on 28 Nov 2025.
Investors can refer to the Sudeep pharma limited IPO RHP-DRHP for detailed information. The issue is managed by ICICI Securities Ltd.,IIFL Capital Services Ltd. as the book running lead manager, while MUFG Intime India Private Limited (Link Intime) is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About sudeep pharma limited
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
Pharmaceutical, Food and Nutrition Business
Specialty Ingredients Business
Triturates
As of December 31, 2024, the company had 704 permanent employees.
Competitve Strengths:
Market leadership with a diversified product portfolio in a high barrier industry
Distinguished global customer base with long-standing relationships with key customers
Well-equipped and regulatory compliant Manufacturing Facilities
Strong research and development capabilities
Investment Objective
General corporate purposes